



FOR IMMEDIATE RELEASE:

Longevity and Stem Cell Expert Thomas Rando M.D., Ph.D. Joins Advisory Board

Palo Alto, CA – July 12, 2022 – Mitrix Bio today announce the appointment of Thomas Rando, M.D., Ph.D. to the Mitrix scientific advisory board. Dr. Rando will join the effort to develop breakthrough mitochondrial transplant technology for use in age-related diseases and longevity medicine.

Dr. Rando has more than 20 years of experience in aging research and has published over 150 research articles on stem cell aging and tissue repair. He is the director of the UCLA Broad Stem Cell Research Center and a professor in the Departments of Neurology and Molecular, Cell and Developmental Biology. Prior to joining UCLA, Dr. Rando served as the director of the Glenn Center for the Biology of Aging at Stanford University School of Medicine and was a professor of neurology and neurological sciences and deputy director of the Stanford Center on Longevity. He is Co-Founder of Fountain Therapeutics.

Rando will join existing Mitrix advisors including Michael Snyder Ph.D., who is Chair of Genetics and Director of Genomics and Personalized Medicine at Stanford University School of Medicine and co-founder of over a dozen biotech firms including Personalis, Q bio, Protometrix, and Affomix. Another Mitrix advisor is Ronjon Nag Ph.D., Adjunct Professor in Genetics in the Stanford School of Medicine and Visiting Fellow at the Stanford Center for Language and Information (CSLI), founder of the R42 Institute, co-founder of Cellmania, Payplant, and Lexicus.

Tom Benson, CEO of Mitrix Bio, says: “We are thrilled to have such an extraordinary team of advisors and scientists, which we see as a testament to how potentially disruptive Mitochondrial Transplant is, not only as a platform for disease cures but a new category of longevity and regenerative medicine.”

Mitochondrial transplant is a new type of regenerative medicine, originally researched at major universities over the past decade. Mitrix Bio is the first team to successfully extend mitochondrial transplant on a practical basis to the large range of adult age-related diseases and longevity. In the Mitrix Process, healthy mitochondria are grown in prototype bioreactors and then transfused into the patient, where they are absorbed into cells to bolster energy production and potentially regenerate aged or dysfunctional tissues. Mitochondrial dysfunction has been implicated in dozens of chronic diseases such as Alzheimer’s Disease, macular degeneration, immune senescence, liver/kidney dysfunction, cardiovascular disease, frailty, mitochondrial mutation diseases, and more.

Visit www.mitrix.bio for more information.

Contact:

Tom Benson
CEO, Mitrix Bio, Inc.

tom@mitrix.bio
(650) 539-8950